TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26765317
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation treatment (ADT)
Study: 7037048
Drug: Ephedrine (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (0.50 mg/kg)
Study: 7037048
Drug: Ephedrine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (0.25 mg/kg)
Study: 26170627
Drug: Lesinurad (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad (tablets or capsules)
Study: 9821420
Drug: 5-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day regimen of amoxicillin/clavulanate in 3 divided doses
Study: 9821420
Drug: 10-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-day regimen of amoxicillin/clavulanate in 3 divided doses
Study: 2195978
Drug: Labetalol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (1, 2, then 3 tablets/day, adjusted according to BP)
Study: 2195978
Drug: Nifedipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (2 tablets/day, recommended dosage)
Study: 31983158
Drug: 10-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day course of triple therapy (Rabeprazole 20 mg, Amoxicillin 1,000 mg, Clarithromycin 500 mg twice daily for 10 days plus 4 days placebo)
Study: 19132203
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg and Simvastatin 10 mg daily (E10/S10; n = 16)
Study: 15562917
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline (20 mg, b.i.d.) for 3 months plus scaling and root planing (SRP)
Study: 11686749
Drug: Solution-focused brief
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution-focused brief therapy (SFBT) training
Study: 9159625
Drug: Low-intensity oral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity oral anticoagulants (INR 2.5 to 3.5) plus aspirin (100 mg/day)
Study: 9159625
Drug: High-intensity oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity oral anticoagulants (INR 3.5 to 4.5)
Study: 29430839
Drug: Carnosine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine supplementation (500 mg per day for 2 months)
Study: 29430839
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg per day for 2 months)
Study: 23161302
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alpha‐2a (180 μg weekly)
Study: 14693624
Drug: Ambulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulation with epidural analgesia (0.08% bupivacaine‐epinephrine plus 1 microg/mL of sufentanil)
Study: 2556727
Drug: Intravenous alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alprazolam
Study: 5134998
Drug: Dimethyltriazeno imidazole
Normalized name: 4-(dimethyltriazeno)imidazole-5-carboxamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethyltriazeno imidazole carboxamide, 2.0 mg/kg for 10 days
Study: 5134998
Drug: Dimethyltriazeno imidazole
Normalized name: 4-(dimethyltriazeno)imidazole-5-carboxamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethyltriazeno imidazole carboxamide, 4.5 mg/kg for 10 days
Study: 31785626
Drug: Cervical artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical artificial insemination (CAI; 3 × 10^9 spermatozoa/90 mL)
Study: 25118962
Drug: Bushen Fangchuan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Fangchuan (BF) tablet
Study: 22238571
Drug: Increased cerebro-cerebral
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased cerebro-cerebral coherence between contralateral M1 and SMA during movement preparation and execution in GTS patients
Study: 17522246
Drug: BSC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSC plus panitumumab, 6 mg/kg i.v., every other week
Study: 837962
Drug: Doxantrazole 200
Normalized name: Contrazole
DrugBank: Zoxazolamine (DB19372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxantrazole 200 mg taken orally 1 hour before exercise test
Study: 837962
Drug: Doxantrazole 400
Normalized name: Contrazole
DrugBank: Zoxazolamine (DB19372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxantrazole 400 mg taken orally
Study: 31805571
Drug: Tamsulosin (TAM)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin (TAM) + Serenoa repens (SR) 320 mg/day + Bovine Colostrum (BC) 30 mg/day
Study: 31060549
Drug: Standardized aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized aqueous extract of Phyllanthus emblica (P. emblica) 250 mg twice daily
Study: 31060549
Drug: Standardized aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized aqueous extract of Phyllanthus emblica (P. emblica) 500 mg twice daily
Study: 25769436
Drug: Natural cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural cocoa consumption (12.7 g natural cocoa, 148 kcal/serving) for 4 weeks
Study: 28893866
Drug: FK506 (tacrolimus)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FK506 (tacrolimus) therapy with target levels <2, 2-3, and 3-5 ng·mL-1
Study: 28893866
Drug: FK506 (tacrolimus)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FK506 (tacrolimus) therapy
Study: 19920417
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (150 mg)
Study: 19920417
Drug: Levobupivacaine 0.33%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.33% (99 mg)
Study: 29170486
Drug: Small-particle size
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-particle size emulsion (SPE) - diameter 0.290 μm, 10 g lipid emulsion, 190 g yoghurt
Study: 29170486
Drug: Control non-emulsion
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control non-emulsion (NE) - 10 g non-emulsion lipid, 190 g yoghurt
Study: 26267219
Drug: Active treatments
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatments (Rupatadine and Desloratadine)
Study: 18166407
Drug: Dorzolamide/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol fixed combination (DTFC) twice daily for 6 months
Study: 11167307
Drug: Oral creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral creatine supplementation (20 g d(‐1) for 7 days)
Study: 16492856
Drug: succinylcholine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 1.0 mg/kg
Study: 31537420
Drug: rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.6 mg/kg
Study: 6472796
Drug: Cysteine Eye-Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine Eye-Gel
Study: 27383495
Drug: Linkus syrup
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linkus syrup
Study: 31274602
Drug: Acetaminophen 15
Normalized name: acetaminophen 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 15 mg/kg
Study: 22572984
Drug: Preseasonal immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preseasonal immunotherapy with olive pollen allergoid
Study: 10397375
Drug: Comparator drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator drugs
Study: 10594475
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg three times daily for 4 consecutive days)
Study: 7795940
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physical practice and rest periods (two sessions)
Study: 30838890
Drug: 12-h intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-h intravenous acetylcysteine regimen (200 mg/kg over 4 h, 50 mg/kg over 8 h)
Study: 30838890
Drug: 20-h intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-h intravenous acetylcysteine regimen (200 mg/kg over 4 h, 100 mg/kg over 16 h)
Study: 25401417
Drug: Liberal erythrocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal erythrocyte transfusion strategy (transfusion when hemoglobin <9 g/dl)
Study: 25401417
Drug: Restrictive erythrocyte
Normalized name: erythrocytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive erythrocyte transfusion strategy (transfusion when hemoglobin <7 g/dl)
Study: 9075649
Drug: Interferon-alpha therapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha therapy
Study: 14649969
Drug: Ginger (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (500 mg orally three times daily for three days)
Study: 14649969
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (10 mg orally three times daily for three days)
Study: 10220013
Drug: G to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: G to A polymorphism at position -1438 of the 5-HT2A receptor gene
Study: 1369707
Drug: Nicardipine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine treatment
Study: 6999546
Drug: PGE2-gel (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2-gel (0.25 mg)
Study: 377896
Drug: PGE2-gel (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2-gel (0.25 mg) with nifedipine
Study: 19884997
Drug: Single Interscalene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Interscalene Block combined with Continuous Intra-bursal Infusion of Ropivacaine (ISB-IB)
Study: 15114199
Drug: Salbutamol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (3 x 2 puffs, 0.2 mg)
Study: 15114199
Drug: Salbutamol combined
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol combined with methylprednisolone (40 mg/day orally)
Study: 9737124
Drug: Ramipril (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (1.25 mg/d, n = 16)
Study: 26138866
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg moxifloxacin (positive control)
Study: 30652317
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (IG) - skin care programme with cream dispensers and electronic monitoring.
Study: 23601071
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day vitamin E and 150 mg/day vitamin C
Study: 12207146
Drug: Cortisol (hydrocortisone)
Normalized name: Corticool
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cortisol (hydrocortisone) 20 mg
Study: 12207146
Drug: Cortisol (hydrocortisone)
Normalized name: Corticool
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cortisol (hydrocortisone) 40 mg
Study: 23343596
Drug: d-amphetamine (AMPH)
Normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (AMPH) 0 mg (placebo)
Study: 19672133
Drug: Adherence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence therapy (during the 12 months after enrollment)
Study: 17088333
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (Dysport) injection (500 Speywood units)
Study: 11591194
Drug: Repeated low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Repeated low-dose allergen exposure (1/5 of the provocative dose)
Study: 2655907
Drug: Fenofibrate 100
Normalized name: fenofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 100 mg three times daily for eight weeks
Study: 2655907
Drug: Fenofibrate 100
Normalized name: fenofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 100 mg three times daily for eight weeks (Group B)
Study: 26282643
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg per day
Study: 22036019
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin placebo
Study: 26282643
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch 30 g per day
Study: 21168000
Drug: High-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirofiban (HDT)
Study: 9748099
Drug: Glucide content
Normalized name: lauroyl/myristoyl methyl glucamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucide content more than 150 g
Study: 17921791
Drug: Topical nimesulide
Normalized name: nimesulide Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nimesulide gel 1% applied 3 times a day for 30 days
Study: 17921791
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied 3 times a day for 30 days
Study: 17921791
Drug: Topical nimesulide
Normalized name: nimesulide Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nimesulide gel 1%
Study: 15656699
Drug: Posaconazole 800
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 800 mg as a single dose (regimen A)
Study: 15656699
Drug: Posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400 mg every 12 hours (regimen B)
Study: 6939000
Drug: Dextroamphetamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine 0.25 mg/kg
Study: 6939000
Drug: Dextroamphetamine 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine 0.50 mg/kg
Study: 28648412
Drug: Restrictive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive hydration with norepinephrine administration (1ml/kg/h initially, then 3ml/kg/h crystalloid infusion after cystectomy)
Study: 28648412
Drug: Liberal hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal hydration (6ml/kg/h standard crystalloid infusion throughout surgery)
Study: 24345529
Drug: Nepafenac 0.3%
Normalized name: NEPAFENAC 0.3% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac 0.3% once daily
Study: 14635083
Drug: Palonosetron 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.75 mg
Study: 19605507
Drug: Dexamethasone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20 mg for patients receiving paclitaxel, 8 mg for those not receiving paclitaxel)
Study: 9649640
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 15 mg/kg
Study: 9504319
Drug: Conventional weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional weight reduction treatment
Study: 11271224
Drug: PUVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA therapy (8‐methoxypsoralen and UVA irradiation)
Study: 3069135
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion at 1 microgram/min for up to 20 min
Study: 3069135
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion (mean dosage of 18.5 ng/min/kg)
Study: 3069135
Drug: Panic attacks
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Panic attacks during isoproterenol infusions
Study: 27824264
Drug: Luphere 3M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luphere 3M Depot (leuprolide acetate dose of 11.25 mg)
Study: 27824264
Drug: Lucrin Depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucrin Depot (leuprolide acetate dose of 11.25 mg)
Study: 26609031
Drug: Oral 25
Normalized name: Neoral 25mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 25 mg dexketoprofen trometamol
Study: 26609031
Drug: Two puff
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two puff lidocaine sprays on cervical mucosa
Study: 12834936
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pethidine
Study: 26609031
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg intravenous paracetamol
Study: 10703393
Drug: Tacrolimus plus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus plus 'low-dose' MMF (TMBIR)
Study: 10703393
Drug: Neoral plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral plus 'low-dose' MMF (NMBIR)
Study: 7037035
Drug: Budesonide, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, 200 micrograms twice daily
Study: 7037035
Drug: Beclomethasone dipropionate,
Normalized name: Beclomethasone Dipropionate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate, 100 micrograms four times daily
Study: 19818720
Drug: Purified vero
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified vero cell rabies vaccine (PVRV, Verorab)
Study: 28199892
Drug: Brief therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief therapy (BT)
Study: 15549275
Drug: Whole drink
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole drink (containing 37.5 g glucose, 75 mg caffeine, ginseng and ginkgo biloba)
Study: 11778791
Drug: pMDI+S (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: pMDI+S (100 microg dose(-1) pressurized metered-dose inhaler with a spacer)
Study: 3318428
Drug: Nabumetone 1,000
Normalized name: nabumetone 1,000 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1,000 mg taken at bedtime
Study: 25311370
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (no access to the website, weekly telephone call as attention-strategy)
Study: 23900058
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation of a bacterial lysate between week 5 and the end of month 7 (intervention group)
Study: 19761514
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (light still touch, same duration as intervention)
Study: 1294028
Drug: Overall early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall early instillation therapy
Study: 30620771
Drug: Hypothetical community-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical community-based health insurance (CBHI) schemes with various benefit package components including insurance coverage for medical consultations, hospitalizations, traffic accidents, pharmaceuticals, transportation, premiums, and prepaid discounts.
Study: 26920602
Drug: Continued novel
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued novel oral anticoagulant (dabigatran, rivaroxaban, or apixaban)
Study: 26920602
Drug: Continued novel
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued novel oral anticoagulant
Study: 26920602
Drug: Interrupted novel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interrupted novel oral anticoagulant
Study: 24457590
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST; 12 total sessions, N=53)
Study: 17197012
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant whole pelvic radiation therapy (WPRT)
Study: 10422040
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen 0.625 mg daily plus progestogen (norgestrel) 150 micrograms for the last 12 days of each 28 day cycle
Study: 343738
Drug: Propranolol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administered 1 to 2 hours prior to operation (Group 2)
Study: 26963897
Drug: DHEA 25
Normalized name: GNP DHEA 25mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 25 mg three times daily for 12 weeks before IVF/ICSI cycles
Study: 17260879
Drug: Benzodiazepine drugs
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine drugs (group 2)
Study: 17260879
Drug: Benzodiazepine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine and GABAergic drugs (group 3)
Study: 11682404
Drug: Large-dose IV
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose IV meperidine (target plasma concentration of 0.8 microg/mL)
Study: 11682404
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of buspirone (30 mg) and meperidine (0.4 microg/mL)
Study: 9728378
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 51)
Study: 3192038
Drug: 40‐g low‐protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40‐g low‐protein diet (LPD)
Study: 354471
Drug: Carbenoxolone 50
Normalized name: carbenoxolone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone 50 mg three times daily
Study: 23692696
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with phase I Coxiella burnetii vaccine (Coxevac-Ceva Sante Animale) during advanced pregnancy
Study: 23692696
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with phase I Coxiella burnetii vaccine
Study: 17524937
Drug: CsA (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA (8 mg/kg/d) plus MMF (30 mg/kg/d) and prednisolone (1 mg/kg/d)
Study: 12568014
Drug: Dihydroartemisinin/pyronaridine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin/pyronaridine combination